{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:28:53Z","timestamp":1787153333363,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cizzle Biotechnology Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CIZ1B is an alternatively spliced protein fragment of the Cyclin-dependent kinase interacting protein 1 (CIP1)-interacting zinc finger protein (CIZ1) complexed with fibrinogen alpha chain (FibA), forming a single parameter protein analyte (CIZ1B-FibA). The CIZ1B blood biomarker has potential to indicate the presence of early-stage lung cancer and could alter clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report configuration and calibration of a sandwich ELISA for measurement of CIZ1B-FibA that uses a new and highly specific CIZ1B exon junction-selective monoclonal antibody to capture the analyte, and an anti-fibrinogen antibody to detect it, in microliter quantities of plasma from lung cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The format is tested across 3 independent sample sets encompassing cancer and control samples, yielding Receiver Operating Characteristic area under curve (ROC AUC) values of 0.82 for Set 1 (n = 48), 0.81 for Set 2 (n = 38), and 0.86 for Set 3 (n = 57), indicating discrimination for individuals with lung cancer including those with stage I or II disease (Set 3). However, comparison of the control plasma samples in each set, which were sourced in 3 countries with site-specific plasma isolation processes, revealed baseline differences indicating a note of caution regarding sensitivity to pre-analytic variables. Application of set-specific thresholds, determined by the maximum Youden Index, returned negative predictive values (NPV) of 95%, 77%, and 97% for Sets 1, 2 and 3, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We describe an affordable and scalable blood test which can measure CIZ1B-FibA and now requires further validation of analytical parameters and investigation of potential biological variables.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfag124","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:15:57Z","timestamp":1785323757000},"source":"Crossref","is-referenced-by-count":0,"title":["A Molecular Tool Set for Measurement of Lung Cancer-Associated Protein Biomarker CIZ1B-FibA in Human Plasma"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4793-6909","authenticated-orcid":false,"given":"Susanna F","family":"Rose","sequence":"first","affiliation":[{"name":"Mammalian Cell Cycle Research Group, Department of Biology, University of York , York ,","place":["United Kingdom"]},{"name":"York Biomedical Research Institute, University of York , York ,","place":["United Kingdom"]},{"name":"Cizzle Biotechnology Ltd , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna F","family":"Pearson","sequence":"additional","affiliation":[{"name":"Mammalian Cell Cycle Research Group, Department of Biology, University of York , York ,","place":["United Kingdom"]},{"name":"York Biomedical Research Institute, University of York , York ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Byrom","sequence":"additional","affiliation":[{"name":"Mammalian Cell Cycle Research Group, Department of Biology, University of York , York ,","place":["United Kingdom"]},{"name":"York Biomedical Research Institute, University of York , York ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F X","family":"Ainscough","sequence":"additional","affiliation":[{"name":"Mammalian Cell Cycle Research Group, Department of Biology, University of York , York ,","place":["United Kingdom"]},{"name":"York Biomedical Research Institute, University of York , York ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-7023","authenticated-orcid":false,"given":"Dawn","family":"Coverley","sequence":"additional","affiliation":[{"name":"Mammalian Cell Cycle Research Group, Department of Biology, University of York , York ,","place":["United Kingdom"]},{"name":"York Biomedical Research Institute, University of York , York ,","place":["United Kingdom"]},{"name":"Cizzle Biotechnology Ltd , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081911101816600_jfag124-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jtho.2017.04.011","article-title":"The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer","volume":"12","author":"Chansky","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026081911101816600_jfag124-B2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening [eng]","volume":"365","author":"National Lung Screening Trial Research Team","year":"2011","journal-title":"N Engl J Med"},{"key":"2026081911101816600_jfag124-B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081911101816600_jfag124-B4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.555331","article-title":"Circulating biomarkers for early stage non-small cell lung carcinoma detection: supplementation to low-dose computed tomography","volume":"11","author":"Kan","year":"2021","journal-title":"Front Oncol"},{"key":"2026081911101816600_jfag124-B5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"2026081911101816600_jfag124-B6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","article-title":"Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study","volume":"24","author":"Nicholson","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026081911101816600_jfag124-B7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (pathfinder): a prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"key":"2026081911101816600_jfag124-B8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41467-018-08072-2","article-title":"Maintenance of epigenetic landscape requires ciz1 and is corrupted in differentiated fibroblasts in long-term culture","volume":"10","author":"Stewart","year":"2019","journal-title":"Nat Commun"},{"key":"2026081911101816600_jfag124-B9","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202103185","article-title":"Prion-like domains drive ciz1 assembly formation at the inactive x chromosome","volume":"221","author":"Sofi","year":"2022","journal-title":"J Cell Biol"},{"key":"2026081911101816600_jfag124-B10","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202409123","article-title":"Epigenetic deprogramming by disruption of ciz1-rna nuclear assemblies in early-stage breast cancers","volume":"224","author":"Turvey","year":"2025","journal-title":"J Cell Biol"},{"key":"2026081911101816600_jfag124-B11","doi-asserted-by":"crossref","first-page":"E3128","DOI":"10.1073\/pnas.1210107109","article-title":"Variant ciz1 is a circulating biomarker for early-stage lung cancer","volume":"109","author":"Higgins","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081911101816600_jfag124-B12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clinbiochem.2016.11.015","article-title":"A quantitative immunoassay for lung cancer biomarker ciz1b in patient plasma","volume":"50","author":"Coverley","year":"2017","journal-title":"Clin Biochem"},{"key":"2026081911101816600_jfag124-B13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1242\/jcs.01599","article-title":"Ciz1 promotes mammalian DNA replication","volume":"118","author":"Coverley","year":"2005","journal-title":"J Cell Sci"},{"key":"2026081911101816600_jfag124-B14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2026081911101816600_jfag124-B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","article-title":"Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice","volume":"5","author":"Trevethan","year":"2017","journal-title":"Front Public Health"},{"key":"2026081911101816600_jfag124-B16"},{"key":"2026081911101816600_jfag124-B17","author":"Eng"},{"key":"2026081911101816600_jfag124-B18","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"2026081911101816600_jfag124-B19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A practical guide to immunoassay method validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"key":"2026081911101816600_jfag124-B20","author":"Blanco"},{"key":"2026081911101816600_jfag124-B21","author":"Hinkel"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article-pdf\/doi\/10.1093\/jalm\/jfag124\/70709266\/jfag124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article-pdf\/doi\/10.1093\/jalm\/jfag124\/70709266\/jfag124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:10:23Z","timestamp":1787152223000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/advance-article\/doi\/10.1093\/jalm\/jfag124\/8766087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfag124","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"jfag124"}}